Cited 20 times in
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이병완 | - |
dc.date.accessioned | 2019-02-12T16:42:10Z | - |
dc.date.available | 2019-02-12T16:42:10Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/167094 | - |
dc.description.abstract | INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have demonstrated favorable effects in patients with type 2 diabetes (T2D). However, there are limited reports in the literature regarding the glucose-lowering effects of SGLT2 inhibitors in actual clinical settings. METHODS: The post-marketing surveillance data from a longitudinal prospective study of 2007 patients with T2D who were prescribed dapagliflozin (10 mg/day) were analyzed (ClinicalTrials.gov, NCT02252224). RESULTS: After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respectively. Both body weight and HbA1c were reduced in 67.7% of patients, and HbA1c was lowered in 75.1%. Younger age, male sex, shorter diabetes duration, higher baseline HbA1c and estimated glomerular filtration rate (eGFR), and having dapagliflozin as add-on therapy were associated with stronger HbA1c reductions after dapagliflozin use (all P < 0.05). Moreover, subgroup analysis of eGFR of subjects with renal hyperfiltration (eGFR ≥ 120 ml/min/1.73 m2) showed the largest reduction in glucose level (% change, - 9.5; 95% CI - 6.8 to - 12.3 for HbA1c; P < 0.001). Multivariable logistic regression analysis showed that recent T2D diagnosis and higher HbA1c at baseline in patients who received an add-on regimen of dapagliflozin were statistically significantly associated with a dapagliflozin response (all P < 0.05). CONCLUSIONS: Dapagliflozin provides benefits for glycemic control and body weight. Patients in a relatively early stage of the course of diabetes with renal hyperfiltration might be more suitable for and gain maximal benefit from dapagliflozin treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer Healthcare | - |
dc.relation.isPartOf | DIABETES THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Eugene Han | - |
dc.contributor.googleauthor | Ari Kim | - |
dc.contributor.googleauthor | Sung Jae Lee | - |
dc.contributor.googleauthor | Je-Yon Kim | - |
dc.contributor.googleauthor | Jae Hyeon Kim | - |
dc.contributor.googleauthor | Woo Je Lee | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.identifier.doi | 10.1007/s13300-018-0470-9 | - |
dc.contributor.localId | A02796 | - |
dc.relation.journalcode | J02908 | - |
dc.identifier.eissn | 1869-6953 | - |
dc.identifier.pmid | 29998370 | - |
dc.subject.keyword | Clinical trials | - |
dc.subject.keyword | Nephropathy | - |
dc.subject.keyword | Obesity | - |
dc.subject.keyword | Pathophysiology | - |
dc.subject.keyword | SGLT2 inhibitors | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.citation.volume | 9 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1689 | - |
dc.citation.endPage | 1701 | - |
dc.identifier.bibliographicCitation | DIABETES THERAPY, Vol.9(4) : 1689-1701, 2018 | - |
dc.identifier.rimsid | 58076 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.